FRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-10), Fresh Tracks Therapeutics's current share price is $0.94. Fresh Tracks Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $918.09. Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio for today is 0.00.
The historical rank and industry rank for Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Fresh Tracks Therapeutics's highest Cyclically Adjusted PB Ratio was 1.80. The lowest was 0.01. And the median was 0.19.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Fresh Tracks Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $1.662. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $918.09 for the trailing ten years ended in Dec. 2023.
The historical data trend for Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresh Tracks Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 0.94 | / | 918.09 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresh Tracks Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Fresh Tracks Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 1.662 | / | 129.4194 | * | 129.4194 | |
= | 1.662 |
Current CPI (Dec. 2023) = 129.4194.
Fresh Tracks Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 2,131.640 | 99.695 | 2,767.210 |
201406 | 2,033.632 | 100.560 | 2,617.271 |
201409 | 1,944.219 | 100.428 | 2,505.478 |
201412 | 1,810.391 | 99.070 | 2,364.999 |
201503 | 1,706.722 | 99.621 | 2,217.230 |
201506 | 1,626.524 | 100.684 | 2,090.739 |
201509 | 1,633.460 | 100.392 | 2,105.770 |
201512 | 1,562.044 | 99.792 | 2,025.794 |
201603 | 1,485.445 | 100.470 | 1,913.453 |
201606 | 1,452.567 | 101.688 | 1,848.696 |
201609 | 1,364.396 | 101.861 | 1,733.532 |
201612 | 1,286.745 | 101.863 | 1,634.845 |
201703 | 1,209.143 | 102.862 | 1,521.322 |
201706 | 1,116.723 | 103.349 | 1,398.422 |
201709 | 1,029.269 | 104.136 | 1,279.172 |
201712 | 918.610 | 104.011 | 1,143.012 |
201803 | 840.693 | 105.290 | 1,033.360 |
201806 | 773.791 | 106.317 | 941.935 |
201809 | 752.166 | 106.507 | 913.979 |
201812 | 704.057 | 105.998 | 859.627 |
201903 | 606.239 | 107.251 | 731.550 |
201906 | 572.914 | 108.070 | 686.097 |
201909 | 105.001 | 108.329 | 125.443 |
201912 | 40.189 | 108.420 | 47.973 |
202003 | 27.423 | 108.902 | 32.590 |
202006 | 33.592 | 108.767 | 39.970 |
202009 | 26.952 | 109.815 | 31.764 |
202012 | 22.802 | 109.897 | 26.853 |
202103 | 19.523 | 111.754 | 22.609 |
202106 | 13.981 | 114.631 | 15.785 |
202109 | 10.127 | 115.734 | 11.324 |
202112 | 9.389 | 117.630 | 10.330 |
202203 | 6.049 | 121.301 | 6.454 |
202206 | 5.812 | 125.017 | 6.017 |
202209 | 3.725 | 125.227 | 3.850 |
202212 | 2.383 | 125.222 | 2.463 |
202303 | 1.670 | 127.348 | 1.697 |
202306 | 1.353 | 128.729 | 1.360 |
202309 | 1.847 | 129.860 | 1.841 |
202312 | 1.662 | 129.419 | 1.662 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Monica E. Luchi | officer: Chief Medical Officer | 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
Reginald L Hardy | director, officer: CHAIRMAN OF THE BOARD | |
David R. Mcavoy | officer: General Counsel and CCO | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Deepak Chadha | officer: Chief Research & Dev. Officer | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Vijay B Samant | director | 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Jose Breton | officer: Chief Accounting Officer | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Robert Busard Brown | director, officer: Chief Executive Officer | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Andrew D Sklawer | officer: COO and Secretary | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
Dennison T Veru | director | C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024 |
Marchio Albert N Ii | officer: Chief Financial Officer | |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Sanjeev Ahuja | officer: Chief Medical Officer | 121 3RD STREET NW, CARMEL IN 46032 |
Adam Scott Levy | officer: Chief Business Officer | C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301 |
William Ju | director | 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301 |
R Michael Carruthers | officer: Chief Financial Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
From GuruFocus
By GlobeNewswire • 12-19-2023
By Marketwired • 07-21-2023
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 06-15-2022
By Stock market mentor Stock market mentor • 01-11-2023
By sperokesalga sperokesalga • 03-30-2023
By PurpleRose PurpleRose • 07-20-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By GuruFocusNews GuruFocusNews • 06-01-2022